GlassScriptPhysician profile
Alexis Passingham
NPI 1568808251
$3,846.68
in general payments reported to CMS, 2019-2025
36 companies · $16.69 in 2025
The $16.69 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,264 · 2022: $969 · 2023: $792 · 2024: $805 · 2025: $16.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,614.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,613.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $702.52 | 2021-2024 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $418.28 | 2021-2024 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $343.52 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $219.67 | 2021-2024 | Xifaxan, Trulance |
| Lilly USA, LLC | $179.16 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $158.92 | 2021-2024 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $142.78 | 2022 | |
| Pfizer INC. | $140.29 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $131.38 | 2022-2023 | |
| Astellas Pharma US INC | $121.31 | 2021-2024 | Veozah |
| Glaxosmithkline, LLC. | $119.42 | 2021-2024 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $94.36 | 2021-2023 | Belsomra |
| Abbott Laboratories | $90.47 | 2022-2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $87.16 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.37 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $82.44 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $77.95 | 2022 | |
| Exact Sciences Corporation | $70.94 | 2023 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $68.66 | 2022-2023 | |
| Biohaven Pharmaceuticals, INC. | $64.63 | 2021 | |
| Axsome Therapeutics, INC. | $57.95 | 2023-2024 | Auvelity |
| Kowa Pharmaceuticals America, INC. | $55.18 | 2021-2023 | Seglentis |
| Esperion Therapeutics, INC. | $44.92 | 2021-2023 | Nexletol |
| Horizon Therapeutics Plc | $42.12 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $41.61 | 2023-2024 | Rexulti |
| Idorsia Pharmaceuticals US INC | $29.43 | 2022-2023 | Quviviq |
| Tolmar, INC. | $27.89 | 2023 | |
| Antares Pharma, INC. | $27.29 | 2021-2022 | |
| Lundbeck LLC | $24.32 | 2024 | Rexulti |
| Indivior INC. | $23.61 | 2024 | Sublocade |
| Amneal Pharmaceuticals LLC | $15.50 | 2021 | |
| Merz North America, INC. | $15.44 | 2024 | |
| Arbor Pharmaceuticals, INC. | $14.68 | 2021 | |
| Bausch Health US, LLC | $14.36 | 2021 | |
| Almatica Pharma LLC | $11.27 | 2021 | |
| Genentech USA, INC. | $3.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexis Passingham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.